Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Lupus Vaccines
Weizmann Institute of Science, Department of Immunology describes research in lupus vaccines
March 12th, 2008
Scientists discuss in 'A peptide that ameliorates lupus up-regulates the diminished expression of early growth response factors 2 and 3' new findings in lupus. According to recent research published in the Journal of Immunology, "Expansion of autoreactive T cells and their resistance to anergy was demonstrated in systemic lupus erythematosus (SLE). A pair of transcription factors, early growth response 2 (Egr-2) and 3 (Egr-3), are negative regulators of T cell activation that were shown to be important in anergy." "A peptide (designated hCDR1 for human CDR1) based on the CDR-1 of an anti-DNA Ab ameliorated SLE in both induced and spontaneous lupus models. Our...
Source: Vaccine Weekly (2008-03-12)
|
